Fagron NV

  • Market Cap: N/A
  • Industry: Retailing
  • ISIN: BE0003874915
EUR
20.75
-0.2 (-0.95%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Fagron NV stock-summary
stock-summary
Fagron NV
Retailing
Fagron NV, formerly Arseus NV, is a Belgium-based company that is active in the healthcare sector. It operates as a research and development (R&D) scientific pharmaceutical compounding supplier and operates through four segments: The Fagron Specialty Pharma Services segment comprises personalized medication that is produced in the Company's compounding facilities; the Fagron Trademarks segment encompasses concepts and formulations developed by the Company's research and development (R&D) team; Fagron Essentials comprises pharmaceutical raw materials, equipment and supplies for pharmacies, and the HL Technology segment includes the development and production of precision components and orthopedic tools for dental and medical professionals.
Company Coordinates stock-summary
Company Details
Venecoweg 20A , NAZARETH None : 9810
stock-summary
Tel: 32 80 012880
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Koen Hoffman
Independent Chairman of the Board representing AHOK BVBA
Mr. Rafael Padilla
Chief Executive Officer, Member of the Executive Committee, Director
Mrs. Karin de Jong
Chief Financial Officer, Executive Director, Member of the Executive Committee
Mr. Marc Coucke
Director representing Alychlo NV
Mr. Michael Schenck
Director representing Michael Schenck BVBA
Ms. Veerle Deprez
Independent Director
Ms. Giulia Van Waeyenberge
Independent Director representing Vanzel G.Comm.V.
Mr. Robert ten Hoedt
Non-Executive Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
157 Million
(Quarterly Results - Dec 2012)
Net Profit:
stock-summary
Industry

Retailing

stock-summary
Market cap

EUR 1,536 Million ()

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.55

stock-summary
Return on Equity

0.00%

stock-summary
Price to Book

3.06